EPOCH方案治疗复发耐药NHL临床疗效

目的：评价EPOCH方案作为挽救方案的疗效及耐受性。方法：2004年6月至2006年12月应用EP-OCH方案治疗我院收治的复发耐药中高度恶性非霍奇金淋巴瘤（NHL）31例，每例至少接受过2个化疗方案的治疗，采用VP-1650mg／m^2/d、ADM或THP10mg／m^2／d、VCR0．4mg／m^2／d持续静脉滴注第1—4天。CTX750mg／m^2／d静推第6天，强的松60rag／m^2／d口服第1—5天，21天为1个疗程。结果：评价疗效者31例，评价不良反应疗程数为67，总有效率54．9％，其中完全缓解6例（19．4％），部分缓解11例（35．5％）。不良反应为骨髓抑制，其他系统不良反应少见。结论：EPOCH作为复发耐药中高度恶性NHL的挽救化疗方案经济有效，毒性可耐受。通过持续静脉滴注的给药途径可能减低肿瘤细胞的耐药率和化学毒性。

Clinical outcome of patients with relapse or refractory non-Hodgkin''''s lymphoma treated by EPOCH regimen

Objective:To evaluate the efficacy and toxicity of EPOCH regimen as salvage chemotherapy regimen in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).Methods:All the 15 patients from 2004 to 2006 were treated with EPOCH regimen previously treated by at least 2 kinds of chemotherapy regimen.Vp-16 mg/m2/d,ADM or THP 10mg/m2/dand VCR 0.4mg/m2/dcontinuous infusion on days 1-4,CTX 750mg/m2/dinfusion on fifth day,every 21 days.Results:All the 31 patients were assessable.The over all response rate was 54.9%,CR19.4%,PR35.5%.Major toxicity was myelosuppression.Other toxicities was mild.Conclusion:EPOCH regimen used as standard salvage regimen is effective and well tolerant for the patients with relapsed or refractory non-Hodgkin's lymphoma.Continuous infusion schedules of several chemotherapeutic agents may partially reverse chemo-resistance and reduce toxicity.